Immune Checkpoint Inhibitors and Lupus Erythematosus
Open Access
- 15 February 2024
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (2) , 252
Abstract
Immune checkpoint inhibitors (ICIs) are the standard of care for a growing number of malignancies. Unfortunately, they are associated with a broad range of unique toxicities that mimic the presentations of primary autoimmune conditions. These adverse events are termed immune-related adverse events (irAEs), of which ICI-lupus erythematosus (ICI-LE) constitutes a small percentage. Our review aims to describe the available literature on ICI-LE and ICI treatment for patients with pre-existing lupus. Most diagnoses of ICI-LE had findings of only cutaneous lupus; four diagnoses of ICI-LE had systemic lupus manifestations. Over 90% (27 of 29) of cases received anti-PD-1/PDL-1 monotherapy, 1 received combination therapy, and 1 received only anti-CTLA-4 treatment. About three-fourths (22 of 29 or 76%) of patients with ICI-lupus were managed with topical steroids, 13 (45%) received hydroxychloroquine, and 10 (34%) required oral corticosteroids. In our case series, none of the patients with pre-existing lupus receiving ICI therapy for cancer had a flare of their lupus, but few had de novo irAE manifestations, all of which were characterized as low-grade. The review of the literature yielded seven ICI-LE flares from a total of 27 patients with pre-existing lupus who received ICI. Most flares were manageable without need for ICI cessation.Keywords
Funding Information
- SECURED (5KL2TR002387-05, T32CA009566)
- National Cancer Institute (5KL2TR002387-05, T32CA009566)
This publication has 66 references indexed in Scilit:
- Understanding the tumor microenvironment for effective immunotherapyMedicinal Research Reviews, 2020
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort StudyArthritis & Rheumatology, 2019
- Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancerCancer Immunology, Immunotherapy, 2019
- Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single‐Center Cohort of Sixty‐One PatientsArthritis & Rheumatology, 2019
- CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation2017
- Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28European Journal of Immunology, 2017
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersJAMA Oncology, 2016
- The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- Abnormal CTLA‐4 function in T cells from patients with systemic lupus erythematosusEuropean Journal of Immunology, 2010
- CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysisHuman Genetics, 2005